ILLUMINA, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ILMN in the last 30 days.
See all $ILMN insider activity →Illumina, Inc. (ILMN) CEO Jacob Thaysen reported a transaction involving the disposal of 1,303 shares at $293.69 per share, according to an SEC Form 4 filing. Thaysen remains a beneficial owner of 107,770 shares. The transaction occurred on October 5, 2026.
Illumina (ILMN) shares fell 5.8% to $276.74 after hitting a 52-week high of $309.35, as investors took profits. The stock trades at 52 times earnings, with analysts' average price target below current levels. Insider selling of over $436 million and a 'hold' consensus rating contributed to the decline. The broader market's rise highlighted the stock-specific nature of the pullback.
Vaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ILMN (ILLUMINA, INC.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 2 bearish.
Recent ILMN coverage spans financial news, market movers and earnings.
Small insider purchase of Illumina stock.
The stock is under pressure as valuation concerns and insider sell‑off outweigh recent momentum.
Shares may continue to climb on strong top‑line growth and optimistic full‑year guidance.
Analyst upgrades are driving a short‑term rally; the stock may face pressure if targets are not met.
Analyst rating maintenance with a higher price target may generate modest buying pressure.
AlphAI scores every news story that mentions ILMN with an AI model for sentiment and relevance, and aggregates insider trades from ILLUMINA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Illumina, Inc. (ILMN) CEO Jacob Thaysen reported a transaction involving the disposal of 1,303 shares at $293.69 per share, according to an SEC Form 4 filing. Thaysen remains a beneficial owner of 107,770 shares. The transaction occurred on October 5, 2026.
1 min readIllumina (ILMN) shares fell 5.8% to $276.74 after hitting a 52-week high of $309.35, as investors took profits. The stock trades at 52 times earnings, with analysts' average price target below current levels. Insider selling of over $436 million and a 'hold' consensus rating contributed to the decline. The broader market's rise highlighted the stock-specific nature of the pullback.
1 min readVaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
3 min readIllumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.
2 min readRBC Capital maintained an Outperform rating and $310 price target for Illumina, implying a 13.5% upside. The firm cited sustained clinical growth, particularly in oncology, and Illumina's robust market position in next-gen sequencing. According to RBC, the company benefits from low market penetration and rising demand for genetic testing.
2 min readAnalysts updated ratings and price targets for multiple companies. Estee Lauder (EL) was upgraded to Overweight with a new target of $108 by Barclays. Nike (NKE) was downgraded to Neutral with a target reduced to $35 by CTBC. Intel (INTC) and Nvidia (NVDA) saw target increases, while Tesla (TSLA) was kept at Reduce with a higher target.
2 min readGuggenheim raised its price target for Illumina to $305 from $226 while maintaining a buy rating. The company's stock is currently trading at $273.68, with a 5-day change of +0.62% and a 1-year change of +108.66%.
1 min readNovacyt S.A. reported H1 2026 revenue of GBP 11.6 million, up 9% year-on-year, driven by acquisition and organic growth. Gross margin declined due to product mix, while restructuring reduced operating expenses. The company expects cost savings in 2027 and anticipates future growth from a partnership with Illumina and new product launches.
1 min readAnalysts updated ratings and price targets for several companies. Datadog (DDOG) was upgraded to buy, PepsiCo (PEP) downgraded to hold, Roblox (RBLX) to underperform, and Coinbase (COIN) maintained at neutral with a higher target. Other companies affected include CF Industries (CF), First Solar (FSLR), Atlassian (TEAM), Illumina (ILMN), Nike (NKE), and Okta (OKTA).
2 min readIllumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.
2 min read
